Long Term Follow-up Study of Type-1 Gaucher Subjects Post FLT201 Dose (GALILEO-2)

Last updated: August 6, 2024
Sponsor: Freeline Therapeutics
Overall Status: Active - Recruiting

Phase

1/2

Condition

Gaucher Disease

Treatment

FLT201

Clinical Study ID

NCT06545136
FLT201-02
  • Ages > 18
  • All Genders

Study Summary

This is a multicenter, long-term, follow-up trial of participants with Gaucher disease type 1 who received FLT201 treatment in a preceding clinical trial. Participants will be followed for 5 years post-treatment.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Participants who have previously received FLT201 (including those who may haverequired recommencement or initiation of ERT/substrate reduction therapy [SRT]).
  1. Participants able to give full informed consent and able to comply with allrequirements of the trial.

Exclusion

Exclusion Criteria:

  • n/a

Study Design

Total Participants: 75
Treatment Group(s): 1
Primary Treatment: FLT201
Phase: 1/2
Study Start date:
May 13, 2024
Estimated Completion Date:
May 31, 2029

Connect with a study center

  • Hospital de Clinicas de Porto Alegre (HCPA)

    Porto Alegre,
    Brazil

    Site Not Available

  • Hospital Quironsalud Zaragoza

    Zaragoza,
    Spain

    Active - Recruiting

  • Salford Royal Hospital

    Salford,
    United Kingdom

    Site Not Available

  • Lysosomal Rare Disorders Research and Treatment Center

    Fairfax, Virginia 22030-6066
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.